[1] |
|
[2] |
VISSEREN F L J, MACH F, SMULDERS Y M,et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J, 2021, 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484.
|
[3] |
SONG P K, MAN Q Q, LI H,et al. Trends in lipids level and dyslipidemia among Chinese adults,2002-2015[J]. Biomed Environ Sci, 2019, 32(8):559-570. DOI: 10.3967/bes2019.074.
|
[4] |
|
[5] |
LI Y Z, TENG D, SHI X G,et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J]. BMJ, 2020, 369:m997. DOI: 10.1136/bmj.m997.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
ZHANG M, DENG Q, WANG L,et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults:a nationally representative survey of 163,641 adults[J]. Int J Cardiol, 2018, 260:196-203. DOI: 10.1016/j.ijcard.2017.12.069.
|
[12] |
MACH F, BAIGENT C, CATAPANO A L,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1):111-188. DOI: 10.1093/eurheartj/ehz455.
|
[13] |
BAIGENT C, BLACKWELL L, EMBERSON J,et al. Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet, 2010, 376(9753):1670-1681. DOI: 10.1016/s0140-6736(10)61350-5.
|
[14] |
D'AGOSTINO R B S, VASAN R S, PENCINA M J,et al. General cardiovascular risk profile for use in primary care:the Framingham Heart Study[J]. Circulation, 2008, 117(6):743-753. DOI: 10.1161/CIRCULATIONAHA.107.699579.
|
[15] |
SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms:new models to estimate 10-year risk of cardiovascular disease in Europe[J]. Eur Heart J, 2021, 42(25):2439-2454. DOI: 10.1093/eurheartj/ehab309.
|
[16] |
HIPPISLEY-COX J, COUPLAND C, VINOGRADOVA Y,et al. Derivation and validation of QRISK,a new cardiovascular disease risk score for the United Kingdom:prospective open cohort study[J]. BMJ, 2007, 335(7611):136. DOI: 10.1136/bmj.39261.471806.55.
|
[17] |
YANG X, LI J, HU D,et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population:the China-PAR project (prediction for ASCVD risk in China)[J]. Circulation, 2016, 134(19):1430-1440. DOI: 10.1161/CIRCULATIONAHA.116.022367.
|
[18] |
MILLETT E R C, PETERS S A E, WOODWARD M. Sex differences in risk factors for myocardial infarction:cohort study of UK Biobank participants[J]. BMJ, 2018, 363:k4247. DOI: 10.1136/bmj.k4247.
|
[19] |
REGITZ-ZAGROSEK V, KARARIGAS G. Mechanistic pathways of sex differences in cardiovascular disease[J]. Physiol Rev, 2017, 97(1):1-37. DOI: 10.1152/physrev.00021.2015.
|
[20] |
BARCENA DE ARELLANO M L, POZDNIAKOVA S, KÜHL A A,et al. Sex differences in the aging human heart:decreased sirtuins,pro-inflammatory shift and reduced anti-oxidative defense[J]. Aging (Albany NY), 2019, 11(7):1918-1933. DOI: 10.18632/aging.101881.
|
[21] |
WORMSER D, KAPTOGE S, DI ANGELANTONIO E,et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease:collaborative analysis of 58 prospective studies[J]. Lancet, 2011, 377(9771):1085-1095. DOI: 10.1016/s0140-6736(11)60105-0.
|